Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
Recent publication
The New England Journal of Medicine reports in its current issue on the anti-tumour activity and safety of tarlatamab. Tarlatamab is an immunotherapeutic agent used in the third-line or later-stage treatment of small-cell lung cancer. The phase II clinical trial involved 220 patients from 57 centres in 17 European countries, including the University Hospital Krems. Patients with advanced small cell lung cancer received 10 mg or 100 mg of tarlatamab intravenously every two weeks. The international DeLLphi-301 study, in which researchers from the Clinical Division of Pneumology at the University Hospital Krems participated, investigated the efficacy of tarlatamab and its side effects, pharmacokinetic properties and immunogenicity.
DeLLphi-301 Investigators, Handzhiev S. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. New England Journal of Medicine. 2023 Oct 20. Epub 2023 Oct 20. doi: 10.1056/NEJMoa2307980
OA Dr. Sabin Handzhiev
Division of Pneumology (University Hospital Krems)
OA Clin. Ass. Prof. DDr. Klaus Hackner
Division of Pneumology (University Hospital Krems)
